Evidence map›Paper›PMID 37916144›Full record

SynthesisFrontiers in endocrinology2023

Management of small cell lung cancer complicated with paraneoplastic Cushing's syndrome: a systematic literature review.

Yanlong Li, Caiyu Li, Xiangjun Qi, Ling Yu, Lizhu Lin

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. [Pulmonary neuroendocrine tumors : Current review].Radiologie (Heidelberg, Germany) · 2024
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Yanlong Li *The First Clinical School of Guangzhou University of Chinese Medicine, Guangzhou, China.
Caiyu Li *The First Clinical School of Guangzhou University of Chinese Medicine, Guangzhou, China.
Xiangjun Qi *The First Clinical School of Guangzhou University of Chinese Medicine, Guangzhou, China.
Ling YuThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Lizhu LinThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
Guangzhou University of Chinese Medicine · CNFirst Affiliated Hospital of Guangzhou University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Paraneoplastic Cushing's syndrome (PCS) is a rare, but clinically important feature of small cell lung cancer (SCLC) that is associated with even worse prognosis. To identify key considerations in comprehensive management of SCLC patients complicated with PCS, we conducted a systematic review of relevant reports on PubMed and Web of Science, focusing on SCLC with PCS cases. The systematic review analyzed 61 reports published between 1985 and 2022 with a total of 157 SCLC patients included. Out of the 157 patients, 132 (84.1%) patients across 58 (95.1%) reports were diagnosed with ectopic Cushing's syndrome. The immunohistochemical (IHC) staining for adrenocorticotropic hormone (ACTH) was performed on 30 (19.1%) patients across 22 (36.1%) reports and demonstrated encouraging performance. For treatment, chemotherapy and ketoconazole were utilized in 50 (81.97%) and 24 (39.34%) reports, respectively. Regarding cause of death, infection and cancer were equally frequent, each being recorded in 17 (27.87%) reports. To conclude, the majority of PCS cases in SCLC patients were caused by ectopic hormone secretion. In order to make a differential diagnosis, it is recommended to utilize IHC staining for a specific hormone such as ACTH or corticotropin-releasing hormone. In the comprehensive treatment of SCLC with PCS patients, effective management of hypercortisolism and potent safeguarding against infection play two crucial roles. Ultimately, further confirmations are required regarding the specificity and accuracy of IHC staining technique as well as the efficacy and safety of immunotherapy in the treatment of SCLC with PCS patients.

Indexed as

Cushing SyndromeLung NeoplasmsParaneoplastic SyndromesSmall Cell Lung CarcinomaAdrenocorticotropic HormoneCorticotropin-Releasing HormoneHumansAdrenocorticotropic HormoneCorticotropin-Releasing Hormoneimmunohistochemistryinfectionmanagementneuroendocrine tumorparaneoplastic Cushing’s syndromesmall cell lung cancer

Identifiers

PMID37916144
PMCPMC10617025
OpenAlexW4387705578

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.